These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 22173168)

  • 1. The interaction of hepatic lipid and glucose metabolism in liver diseases.
    Bechmann LP; Hannivoort RA; Gerken G; Hotamisligil GS; Trauner M; Canbay A
    J Hepatol; 2012 Apr; 56(4):952-64. PubMed ID: 22173168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.
    Ma KL; Ruan XZ; Powis SH; Chen Y; Moorhead JF; Varghese Z
    Hepatology; 2008 Sep; 48(3):770-81. PubMed ID: 18752326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
    Musso G; Gambino R; Cassader M
    Prog Lipid Res; 2009 Jan; 48(1):1-26. PubMed ID: 18824034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear receptors in liver disease.
    Wagner M; Zollner G; Trauner M
    Hepatology; 2011 Mar; 53(3):1023-34. PubMed ID: 21319202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.
    Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H
    Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
    Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
    Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells.
    Tanner N; Kubik L; Luckert C; Thomas M; Hofmann U; Zanger UM; Böhmert L; Lampen A; Braeuning A
    Drug Metab Dispos; 2018 Apr; 46(4):326-335. PubMed ID: 29330220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action.
    Elhafiz M; Zhao G; Ismail M; Xu D; Das D; Fan S; Cheng N; Yousef BA; Jiang Z; Zhang L
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158657. PubMed ID: 32045698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrauterine metabolic programming alteration increased susceptibility to non-alcoholic adult fatty liver disease in prenatal caffeine-exposed rat offspring.
    Wang L; Shen L; Ping J; Zhang L; Liu Z; Wu Y; Liu Y; Huang H; Chen L; Wang H
    Toxicol Lett; 2014 Jan; 224(3):311-8. PubMed ID: 24239806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging functions of the nuclear receptor LRH-1 in liver physiology and pathology.
    Sun Y; Demagny H; Schoonjans K
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166145. PubMed ID: 33862147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
    Fernandes GW; Bocco BMLC
    Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver X receptors bridge hepatic lipid metabolism and inflammation.
    Liu Y; Qiu DK; Ma X
    J Dig Dis; 2012 Feb; 13(2):69-74. PubMed ID: 22257474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
    Haukeland JW; Dahl TB; Yndestad A; Gladhaug IP; Løberg EM; Haaland T; Konopski Z; Wium C; Aasheim ET; Johansen OE; Aukrust P; Halvorsen B; Birkeland KI
    Eur J Endocrinol; 2012 Mar; 166(3):503-10. PubMed ID: 22170794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.